CN109589340B - Application of mole cricket extract in preparing medicine for treating breast cancer with three yin - Google Patents
Application of mole cricket extract in preparing medicine for treating breast cancer with three yin Download PDFInfo
- Publication number
- CN109589340B CN109589340B CN201710908588.4A CN201710908588A CN109589340B CN 109589340 B CN109589340 B CN 109589340B CN 201710908588 A CN201710908588 A CN 201710908588A CN 109589340 B CN109589340 B CN 109589340B
- Authority
- CN
- China
- Prior art keywords
- mole cricket
- reduced pressure
- petroleum ether
- phase
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Insects & Arthropods (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Husbandry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of mole cricket extract in preparing a medicine for treating breast cancer with three yin. In the application, the preparation method of the mole cricket extract comprises the following steps: (1) extracting mole cricket serving as a raw material with petroleum ether to obtain an extracting solution, and concentrating under reduced pressure until the weight is basically unchanged; (2) separating by high-speed counter-current chromatography, wherein: the solvent system is a mixed solution of chloroform, methanol and water, the upper phase is a stationary phase, and the lower phase is a mobile phase; collecting eluate for 60-120min, and concentrating under reduced pressure. The mole cricket extract has obvious in-vitro inhibitory activity on three-yin breast cancer cells.
Description
Technical Field
The invention relates to an application of mole cricket extract in preparing a medicine for treating breast cancer with three yin.
Background
Chinese patent application CN200410025162.7 discloses an anti-tumor effective fraction extracted from mole cricket and its preparation method, which comprises pulverizing mole cricket, extracting with alcohol solution, extracting with low polarity organic solvent to obtain effective fraction, and the effective fraction has significant anti-tumor activity. Because of the related alcohol solution extraction process, the production cost is high, the industrialization process is complex, and the inhibition effect of the extract on the triple negative breast cancer cells is still to be improved.
Chinese patent application CN201010300103.1 discloses a method for separating pharmacodynamic substances of traditional Chinese medicine mole cricket by using high-speed counter-current chromatography, which comprises the steps of grinding medicinal materials, refluxing and extracting with 70% ethanol aqueous solution, extracting with ethyl acetate after petroleum ether extraction, and obtaining an ethyl acetate extract, wherein the high-speed counter-current chromatography is adopted for separation, a solvent system is a mixed solution of n-hexane, ethanol and water, and the proportion of the mixed solution is n-hexane: ethanol: water 6: 5: 1, the volume of the separation column is 230mL, the mobile phase is the upper phase, the rotating speed is 1000r/min, the flow rate is 1.5mL/min, the sample amount is 400mg, the retention rate of the stationary phase is 48%, the detection wavelength is 245nm, the sample collection time is 30-35min, the measured activity is QGY7703 liver cancer cells, and the cytotoxic activity is 30.47% higher than that of the negative control. The preparation method relates to a multi-step extraction process, is tedious, high in production cost and complex in industrialization process, and the extract has no inhibition effect on triple-negative breast cancer cells.
Disclosure of Invention
The invention aims to solve the technical problem of overcoming the defect of low inhibition activity of the mole cricket extract on three-negative breast cancer cells in the prior art, and provides the application of the mole cricket extract in preparing a medicine for treating three-negative breast cancer. Compared with the active site prepared from the antineoplastic agent paclitaxel and Chinese patent application CN200410025162.7, the mole cricket extract has obvious in-vitro inhibitory activity on triple-negative breast cancer cells.
The invention solves the technical problems through the following technical scheme:
the invention provides an application of mole cricket extract in preparing a medicine for treating breast cancer with three yin, wherein the preparation method of the mole cricket extract comprises the following steps:
(1) extracting mole cricket serving as a raw material with petroleum ether to obtain an extracting solution, and concentrating under reduced pressure until the weight is basically unchanged;
(2) separating by high-speed counter-current chromatography, wherein: the solvent system is a mixed solution of chloroform, methanol and water, the upper phase is a stationary phase, and the lower phase is a mobile phase; collecting eluate for 60-120min, and concentrating under reduced pressure.
In the step (1), the mole cricket, generally known as a traditional Chinese medicine mole cricket, is generally used as a raw material after the whole dried mole cricket is crushed before use, the raw material is crushed mole cricket medicinal material coarse powder, and the moisture content is generally 3-5 wt%.
In step (1), the petroleum ether may be petroleum ether conventionally used in the art, preferably petroleum ether with a boiling range specification of 30-60 ℃, more preferably petroleum ether with a boiling range specification of 60-90 ℃. The inventor finds that the yield of the step is about 15% -20% by adopting petroleum ether with the boiling range specification of 30-60 ℃ for extraction in the research process; the extraction of petroleum ether with boiling range specification of 60-90 deg.C is adopted, and the yield of the step is about 18% -25%.
Wherein, the dosage of the petroleum ether can be the dosage which is conventional in the field, and the ratio of the volume of the petroleum ether to the mass of the mole cricket is preferably 4 to 6, and the unit is g/mL, more preferably 6, and the unit is g/mL.
In step (1), the extraction operation and conditions may be those conventional in the art, such as reflux extraction, and the number of times of extraction is preferably 3 to 4 times, more preferably 3 times.
In step (1), the operation and conditions of the concentration under reduced pressure may be those conventional in the art, and the temperature of the concentration under reduced pressure is preferably 50 to 70 ℃, more preferably 60 ℃.
In the step (2), the separation is carried out in a high-speed countercurrent chromatograph, the equipment model of the high-speed countercurrent chromatograph is Tauto300b, and the column volume of the high-speed countercurrent chromatograph is 300 mL.
In step (2), the rotation speed of the high-speed countercurrent chromatography can be the rotation speed conventionally used in the field, and the flow rate of the mobile phase can be the flow rate conventionally used in the field. Preferably, the rotating speed of the high-speed countercurrent chromatography is 800-1000r/min, and the flow rate of the mobile phase is 1.0-1.5 mL/min. More preferably, the rotating speed of the high-speed countercurrent chromatography is 1000r/min, and the flow rate of the mobile phase is 1.5 mL/min. The inventor finds in the research process that when the rotating speed of the high-speed countercurrent chromatography is 1000r/min and the flow rate of the mobile phase is 1.5mL/min, the separation efficiency can be improved.
In the step (2), the solvent system is divided into a two-phase system at the conventional rotating speed in the field, the upper phase is a stationary phase, the lower phase is a mobile phase, the mole cricket extract enters the mobile phase in the separation process, the eluent is collected for 60-120min, and the organic solvent in the eluent is removed through reduced pressure concentration, so that the mole cricket extract serving as the target product is obtained.
In the step (2), the volume ratio of chloroform, methanol and water in the mixed solution is preferably (5-7):6:6, more preferably 1:1: 1.
In the step (2), the retention rate of the stationary phase is preferably 54%.
In the step (2), the operation and conditions of the concentration under reduced pressure may be those conventional in the art, and the temperature of the concentration under reduced pressure is preferably 50 to 70 ℃, more preferably 60 ℃.
Those skilled in the art know that breast cancer can be classified into different types according to the microscopic characteristics of tumor cells, such as: tumors derived from epithelial cells, sarcomas derived from muscle, fat or connective tissue; breast cancer can also be classified according to proteins on the surface of or within the cancer cell, such as hormone receptor positive or triple negative.
In the invention, the triple negative breast cancer refers to breast cancer with negative expression of Estrogen Receptor (ER), progestational hormone receptor (PR) and human epidermal growth factor receptor 2(Her-2), which accounts for 10-15% of the total number of all breast cancer patients, and has the characteristics of early onset age, high invasiveness, poor prognosis, early local recurrence, distant metastasis and the like, and the probability of visceral metastasis is higher than that of bone metastasis, and spinal cord, meninges, brain, liver and lung metastasis easily occurs.
On the basis of the common knowledge in the field, the above preferred conditions can be combined randomly to obtain the preferred embodiments of the invention.
The reagents and starting materials used in the present invention are commercially available.
The positive progress effects of the invention are as follows: the invention provides an application of mole cricket extract in preparing a medicine for treating breast cancer with three yin. Compared with the active site prepared from the antineoplastic agent paclitaxel and Chinese patent application CN200410025162.7, the mole cricket extract has obvious in-vitro inhibitory activity on triple-negative breast cancer cells.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention. The experimental methods without specifying specific conditions in the following examples were selected according to the conventional methods and conditions, or according to the commercial instructions.
In the following examples, "raw material" refers to "pulverized mole cricket dry crude drug powder".
Example 1
(1)50g of the raw material are extracted by reflux three times by 300mL of petroleum ether (the boiling range is 60-90 ℃), and the mixture is concentrated under reduced pressure at 60 ℃ until no solvent smell exists and the weight is not lost.
(2) Separating by using a TAUTO300B type high-speed counter-current chromatograph, wherein a solvent system is a mixed solution of chloroform, methanol and water, the volume ratio of the chloroform to the methanol to the water in the mixed solution is 1:1:1, an upper phase is a stationary phase, a lower phase is a mobile phase, the rotating speed is 1000r/min, the flow rate is 1.5mL/min, the retention rate of the stationary phase is 54%, detecting the mobile phase by using an Evaporative Light Scattering Detector (ELSD), collecting eluent for 60-120min, and concentrating under reduced pressure at 60 ℃.
Comparative example 1
Extracting 50g of raw materials with 400mL of 95% ethanol under reflux for three times, concentrating under reduced pressure at 60 ℃ until no solvent smell is produced and the weight is not lost, extracting with 300mL of petroleum ether (boiling range is 60-90 ℃) under reflux for three times, and concentrating under reduced pressure at 60 ℃ until the weight is not lost.
Comparative example 2
50g of raw material is extracted by refluxing three times with 300mL of 70% ethanol aqueous solution, extracted by ethyl acetate after petroleum ether (boiling range is 60-90 ℃) is extracted to obtain an ethyl acetate extract, and the ethyl acetate extract is separated by adopting high-speed counter-current chromatography, wherein a solvent system is a mixed solution of normal hexane, ethanol and water, and the proportion of the mixed solution is that the normal hexane: ethanol: water 6: 5: 1, the volume of the separation column is 230mL, the mobile phase is the upper phase, the rotating speed is 1000r/min, the flow rate is 1.5mL/min, the sample amount is 400mg, the retention rate of the stationary phase is 48%, the detection wavelength is 245nm, and the sample collection time is 30-35 min.
Comparative example 3
50g of raw materials are extracted by refluxing with 400mL of 95% ethanol for three times, and the raw materials are concentrated under reduced pressure at 60 ℃ until no solvent smell is generated and the weight is not lost, extracted by refluxing with 300mL of petroleum ether (the boiling range is 60-90 ℃) for three times, and concentrated under reduced pressure at 60 ℃ until the weight is not lost, and the raw materials are separated by adopting high-speed counter-current chromatography, wherein a solvent system is a mixed solution of normal hexane, ethanol and water, and the proportion of the mixed solution is that the normal hexane: ethanol: water 6: 5: 1, the volume of the separation column is 230mL, the mobile phase is the upper phase, the rotating speed is 1000r/min, the flow rate is 1.5mL/min, the sample amount is 400mg, the retention rate of the stationary phase is 48%, the detection wavelength is 245nm, and the sample collection time is 30-35 min.
Comparative example 4
50g of raw material is extracted by refluxing with 400mL of 95% ethanol for three times, and is concentrated under reduced pressure at 60 ℃ until no solvent smell is generated and the weight is not lost, is extracted by refluxing with 300mL of petroleum ether (the boiling range is 60-90 ℃) for three times, and is concentrated under reduced pressure at 60 ℃ until the weight is not lost, a TAUTO300B type high-speed counter-current chromatograph is adopted for separation, a solvent system is a mixed solution of chloroform, methanol and water, the volume ratio of the chloroform, the methanol and the water in the mixed solution is 1:1:1, an upper phase is a stationary phase, a lower phase is a mobile phase, the rotating speed is 1000r/min, the flowing speed is 1.5mL/min, the retention rate of the stationary phase is 54%, an Evaporative Light Scattering Detector (ELSD) is adopted for detecting the mobile phase, eluent of 60-120min is collected, and is concentrated under reduced pressure at 60 ℃ to obtain the product.
Comparative example 5
50g of raw material is extracted by refluxing for three times by 300mL of 70% ethanol aqueous solution, extracted by petroleum ether (boiling range is 60-90 ℃) and then extracted by ethyl acetate to obtain an ethyl acetate extract, the ethyl acetate extract is separated by a TAUTO300B type high-speed counter-current chromatograph, a solvent system is a mixed solution of chloroform, methanol and water, the volume ratio of the chloroform, the methanol and the water in the mixed solution is 1:1:1, an upper phase is a stationary phase, a lower phase is a mobile phase, the rotating speed is 1000r/min, the flow rate is 1.5mL/min, the retention rate of the stationary phase is 54%, the mobile phase is detected by an Evaporative Light Scattering Detector (ELSD), the eluent is collected for 60-120min, and the ethyl acetate extract is obtained by vacuum concentration at 60 ℃.
Comparative example 6
In the research and development process, the inventor finds that when the solvent system in the step (2) in the example 1 is replaced by a dichloromethane-methanol-water system, the separation effect is poor, so that the effective components in the extract are influenced, and the in-vitro inhibitory activity on the triple negative breast cancer cells is reduced; if the solvent system in the step (2) of example 1 is replaced by a chloroform-ethanol-water system, the solution layering time is too long, which greatly affects the separation effect, so that the effective components in the extract are affected, and the in vitro inhibitory activity on triple negative breast cancer cells is greatly reduced.
Effect example 1
The extract obtained in example 1, the extracts obtained in comparative examples 1 to 5, and the control drug paclitaxel were prepared to the concentrations shown in the following table, respectively, and triple negative breast cancer cells MDA-MB-231 were inoculated on a 96-well plate, and the cells were treated with the extracts and the control drug at the corresponding concentrations for 48 hours. Adding 75 μ L of sulforhodamine B (SRB) staining solution (0.4%) prepared by 1% glacial acetic acid into each well, and staining for 10min at room temperature; after discarding the staining solution in each well, the well was washed 3 times with 1% acetic acid to wash off excess SRB dye, 100 μ L of 10mm tris-Base (tris, pH 10.5) solution was added to each well, and the well was shaken at low speed for 5 to 10 minutes on a well plate shaker to dissolve SRB sufficiently, and then the absorbance OD value was measured at a wavelength of 490/630nm using a microplate reader. Wherein: example 1 and comparative examples 1-2 were repeated in three batches.
According to the OD value measured by the microplate reader, the cell survival rate is calculated according to the following formula: survival (%) > OD of treated group/OD of control group × 100%. Inhibition (%) -.
Note: the paclitaxel as the control in the above table is purchased from Shanghai Hotan Biotechnology GmbH, with a purity of 98% (HPLC) or more.
Example 2
(1)50g of the raw material are extracted by reflux three times by 200mL of petroleum ether (boiling range is 60-90 ℃), and concentrated under reduced pressure at 60 ℃ until no solvent smell exists and the weight is not lost.
(2) Separating by using a TAUTO300B type high-speed counter-current chromatograph, wherein a solvent system is a mixed solution of chloroform, methanol and water, the volume ratio of the chloroform to the methanol to the water in the mixed solution is 5:6:6, an upper phase is a stationary phase, a lower phase is a mobile phase, the rotating speed is 1000r/min, the flow rate is 1.5mL/min, the retention rate of the stationary phase is 54%, detecting the mobile phase by using an Evaporative Light Scattering Detector (ELSD), collecting eluent for 60-120min, and concentrating under reduced pressure at 60 ℃.
Example 3
(1)50g of the raw material is extracted by reflux three times by 300mL of petroleum ether (boiling range is 60-90 ℃), and the raw material is concentrated under reduced pressure at 60 ℃ until no solvent smell exists and the weight is not lost.
(2) Separating by using a TAUTO300B type high-speed counter-current chromatograph, wherein a solvent system is a mixed solution of chloroform, methanol and water, the volume ratio of the chloroform to the methanol to the water in the mixed solution is 7:6:6, an upper phase is a stationary phase, a lower phase is a mobile phase, the rotating speed is 1000r/min, the flow rate is 1.5mL/min, the retention rate of the stationary phase is 54%, detecting the mobile phase by using an Evaporative Light Scattering Detector (ELSD), collecting eluent for 60-120min, and concentrating under reduced pressure at 60 ℃.
Effect example 2
The extracts obtained in example 2 and example 3 were measured for their inhibitory rate against triple negative breast cancer cell MDA-MB-231 according to the test method of Effect example 1, and the obtained inhibitory rate values were comparable to those of example 1.
Claims (11)
1. The application of mole cricket extract in preparing a medicine for treating breast cancer with three yin, is characterized in that the preparation method of the mole cricket extract comprises the following steps:
(1) extracting mole cricket serving as a raw material with petroleum ether to obtain an extracting solution, and concentrating under reduced pressure until the weight is basically unchanged; wherein the ratio of the volume of the petroleum ether to the mass of the mole cricket is 4-6, and the unit is mL/g; the extraction is reflux extraction, and the reflux extraction times are 3-4 times;
(2) separating by high-speed counter-current chromatography, wherein: the solvent system is a mixed solution of chloroform, methanol and water, the upper phase is a stationary phase, and the lower phase is a mobile phase; collecting eluate for 60-120min, and concentrating under reduced pressure; wherein the rotating speed of the high-speed countercurrent chromatography is 800-1000r/min, and the flow rate of the mobile phase is 1.0-1.5 mL/min; the volume ratio of chloroform to methanol to water in the mixed solution is (5-7) to 6: 6.
2. The use according to claim 1, wherein in step (1) the petroleum ether is petroleum ether having a boiling range specification of 30 to 60 ℃ or petroleum ether having a boiling range specification of 60 to 90 ℃.
3. The use according to claim 1 or 2 wherein the ratio of the volume of petroleum ether to the mass of mole cricket is 6 in mL/g.
4. The use according to claim 1, wherein in step (1), the temperature of said concentration under reduced pressure is between 50 ℃ and 70 ℃.
5. The use according to claim 4, wherein in step (1), the temperature of the reduced pressure concentration is 60 ℃.
6. The use of claim 1, wherein in step (2), the separation is performed in a high-speed countercurrent chromatograph having the equipment model TAUTO 300B.
7. The use according to claim 1, wherein in step (2), the high speed counter-current chromatography is performed at a rotation speed of 1000r/min and the flow rate of the mobile phase is 1.5 mL/min.
8. The use of claim 1, wherein in step (2), the volume ratio of chloroform, methanol and water in the mixed solution is 1:1: 1.
9. The use according to claim 1, wherein in step (2), the retention of the stationary phase is 54%.
10. The use according to claim 1, wherein in step (2), the temperature of said concentration under reduced pressure is 50-70 ℃.
11. The use according to claim 10, wherein in step (2), the temperature of the reduced pressure concentration is 60 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710908588.4A CN109589340B (en) | 2017-09-29 | 2017-09-29 | Application of mole cricket extract in preparing medicine for treating breast cancer with three yin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710908588.4A CN109589340B (en) | 2017-09-29 | 2017-09-29 | Application of mole cricket extract in preparing medicine for treating breast cancer with three yin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109589340A CN109589340A (en) | 2019-04-09 |
| CN109589340B true CN109589340B (en) | 2022-07-12 |
Family
ID=65955340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710908588.4A Active CN109589340B (en) | 2017-09-29 | 2017-09-29 | Application of mole cricket extract in preparing medicine for treating breast cancer with three yin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109589340B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1582970A (en) * | 2004-06-15 | 2005-02-23 | 上海澳隆科技发展有限公司 | Extraction of effective portion of gryllotalpidae for anti-cancers and its preparation |
| CN101250102A (en) * | 2008-03-31 | 2008-08-27 | 福建农林大学 | Method for extracting phenylacetic acid substance from gryllotalpidae |
| CN101716192A (en) * | 2010-01-07 | 2010-06-02 | 福建农林大学 | Method for separating pharmacodynamic substances of Chinese medicinal mole crickets by utilizing high-speed countercurrent chromatography |
| CN104003923A (en) * | 2014-05-30 | 2014-08-27 | 河南科技大学 | Method for extracting alkaloids compounds from mole cricket and application of compound |
-
2017
- 2017-09-29 CN CN201710908588.4A patent/CN109589340B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1582970A (en) * | 2004-06-15 | 2005-02-23 | 上海澳隆科技发展有限公司 | Extraction of effective portion of gryllotalpidae for anti-cancers and its preparation |
| CN101250102A (en) * | 2008-03-31 | 2008-08-27 | 福建农林大学 | Method for extracting phenylacetic acid substance from gryllotalpidae |
| CN101716192A (en) * | 2010-01-07 | 2010-06-02 | 福建农林大学 | Method for separating pharmacodynamic substances of Chinese medicinal mole crickets by utilizing high-speed countercurrent chromatography |
| CN104003923A (en) * | 2014-05-30 | 2014-08-27 | 河南科技大学 | Method for extracting alkaloids compounds from mole cricket and application of compound |
Non-Patent Citations (1)
| Title |
|---|
| 抗肿瘤中药的研究与开发新进展;杨义芳等;《国际中西医肿瘤研究论坛论文专辑》;20081231;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109589340A (en) | 2019-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111087285B (en) | Method for extracting bibenzyl compounds from dendrobium officinale and application of bibenzyl compounds | |
| EP2329816A1 (en) | An anti-cancer active substance from antrodia camphorata, method for preparing the same and use thereof | |
| CN105237430A (en) | Method for extracting numb-taste substance from Zanthoxylum armatum DC. | |
| CN104262154B (en) | Polyphenolic compound method for preparing monomer in Gnaphalium affine | |
| CN113264974B (en) | Preparation of type B cardiac glycoside and anti-angiogenesis application thereof | |
| WO2020087687A1 (en) | Isopentenyl chalcone compound and preparation method therefor | |
| CN109589340B (en) | Application of mole cricket extract in preparing medicine for treating breast cancer with three yin | |
| CN103784481B (en) | A kind of method and application thereof extracting antitumor component from Cordyceps militaris (L.) Link. | |
| CN103191143B (en) | New application of cardiac glycoside compound | |
| CN102764320B (en) | Psychotria sp. extract, and preparation method and antineoplastic application thereof | |
| CN106674239B (en) | A kind of Viburnum opulus Linn. var. calvescens (Rehd.) Hara f. calvescens branches and leaves lignanoid and extracting method and purposes | |
| CN105037313B (en) | A kind of method of myricetrin and catechin compounds in separation Chinese waxmyrtle bark | |
| CN109589341B (en) | Gryllotalpa extract and its preparation method | |
| CN108836982A (en) | A kind of toad skin active component and preparation method thereof | |
| CN109111444B (en) | Method for separating and purifying caffeine from camellia pollen | |
| CN114605422A (en) | A pair of enantiomer alkaloid dimer compounds, and preparation method and application thereof | |
| CN113527323A (en) | Method for extracting phenolic compounds from tung tree | |
| CN109206392B (en) | Coumarin compound and preparation method and application thereof | |
| CN106045951B (en) | A kind of mysorethorn lactone and its preparation method and purposes | |
| CN103751224B (en) | Method and the application thereof of antitumor component is extracted from Cordyceps militaris (L.) Link. | |
| CN111303185B (en) | Compound with tumor inhibiting activity and extraction method thereof | |
| CN109180467B (en) | Extraction method and application of trinetradecanoic- (20,23) -dienoic acid | |
| CN108676054A (en) | A kind of triterpene compound and its preparation method and application | |
| CN106588853B (en) | One kind phenolic compound containing pyranoid ring and its preparation method and application | |
| CN110075145B (en) | Method for extracting total cardiac glycosides from oleander leaves |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |